Click here to read full article…
NEW YORK (GenomeWeb) – Having spent the last seven years prepping its technology, proteomic diagnostics firm Plaxgen is now moving tests for Alzheimer’s disease and atherosclerosis towards commercialization.
The FDA purchase cheap cialis ensures that the drug is completely safe for use as it is approved by FDA. There are multiple issues that produce impaired hearing sensitivity. viagra rx For example, if someone isn’t managing their stress, the blood pressure medication becomes an “enabler,” – merely allowing deeper prescription canada de cialis stress issues to compound. In this case a preferably discount viagra cialis higher dosage is to be avoided at all costs. First in line is the company’s Alzheimer’s diagnostic, named Amyload, for which it is currently planning a validation study expected to begin in June 2015 and run through approximately January 2016, Plaxgen Founder and CEO Shanmugavel Madasamy told GenomeWeb.
The company plans to offer the test initially out of its Fremont, Calif.-based CLIA facility while simultaneously filing for US Food and Drug Administration 510(k) clearance, he said, noting that it plans to target the test to pharma firms that would use it for selecting patients for clinical trials and measuring response to treatment.